AdvanCell News and Resources

AdvanCell, a clinical-stage radiopharmaceutical company specialising in targeted alpha therapies, has announced an expansion of its collaboration with Eli Lilly and Company to advance innovative cancer treatments. The strengthened partnership will integrate AdvanCell’s proprietary Pb-212 production technology and radionuclide infrastructure

AdvanCell, a radiopharmaceuticals biotech, has secured $112 million in an oversubscribed Series C financing round. The funding was co-led by SV Health Investors, Sanofi Ventures, Abingworth, and SymBiosis, with additional participation from Morningside, Tenmile, Brandon Capital, and others. The investment